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Time Course and Mechanism of Myocardial Catecholamine
Release During Transient Ischemia In Vivo
Thomas W. Lameris, MD; Sandra de Zeeuw, MSc; Gooitzen Alberts, BSc; Frans Boomsma, PhD;
Dirk J. Duncker, MD, PhD; Pieter D. Verdouw, PhD; Arie J. Man in ’t Veld, MD, PhD;
Anton H. van den Meiracker, MD, PhD
Background—Elevated concentrations of norepinephrine (NE) have been observed in ischemic myocardium. We
investigated the magnitude and mechanism of catecholamine release in the myocardial interstitial fluid (MIF) during
ischemia and reperfusion in vivo through the use of microdialysis.
Methods and Results—In 9 anesthetized pigs, interstitial catecholamine concentrations were measured in the perfusion
areas of the left anterior descending coronary artery (LAD) and the left circumflex coronary artery. After stabilization,
the LAD was occluded for 60 minutes and reperfused for 150 minutes. During the final 30 minutes, tyramine (154 nmol z
kg21 z min21) was infused into the LAD. During LAD occlusion, MIF NE concentrations in the ischemic region
increased progressively from 1.060.1 to 5246125 nmol/L. MIF concentrations of dopamine and epinephrine rose from
0.460.1 to 43.969.5 nmol/L and from ,0.2 (detection limit) to 4.760.7 nmol/L, respectively. Local uptake-1 blockade
attenuated release of all 3 catecholamines by .50%. During reperfusion, MIF catecholamine concentrations returned to
baseline within 120 minutes. At that time, the tyramine-induced NE release was similar to that seen in nonischemic
control animals despite massive infarction. Arterial and MIF catecholamine concentrations in the left circumflex
coronary artery region remained unchanged.
Conclusions—Myocardial ischemia is associated with a pronounced increase of MIF catecholamines, which is at least in
part mediated by a reversed neuronal reuptake mechanism. The increase of MIF epinephrine implies a (probably
neuronal) cardiac source, whereas the preserved catecholamine response to tyramine in postischemic necrotic
myocardium indicates functional integrity of sympathetic nerve terminals. (Circulation. 2000;101:2645-2650.)
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Myocardial ischemia is associated with a marked accu-mulation of norepinephrine (NE) in ischemic tissue.1–4
In vitro studies suggest that this is caused by nonexocytotic
release of NE from cardiac sympathetic nerves.5–7 In contrast
to the normally occurring exocytotic NE release, this non-
exocytotic NE release is (1) calcium independent, (2) not
under influence of local or central sympathetic stimulation,
and (3) not affected by presynaptic inhibition.7 Interestingly,
these in vitro studies in the sympathetically dominant rat
heart also suggest that the ischemia-induced nonexocytotic
NE release can be attenuated by neuronal uptake-1 (U1)
blockade, indicating that under ischemic conditions, the U1
mechanism is reversed and can operate as a carrier for
outward instead of inward NE transport.5,6 However, this has
not been investigated in parasympathetically dominant hu-
man and porcine hearts in vivo. Furthermore, little is known
about the myocardial release of epinephrine (E) and dopa-
mine (DA) in the ischemic heart in vivo; this is of particular
interest because cardiac E release has been reported in in vitro
studies and in healthy elderly men and patients with severe
congestive heart failure at rest and during exercise.8–11
Microdialysis allows the measurement of catecholamine
concentrations in the myocardial interstitial fluid (MIF) in
vivo and the investigation of the mechanisms that underlie
their local release and clearance.12 Using an in vivo porcine
model, we investigated the time course and magnitude of
changes in MIF concentrations of catecholamines during
severe myocardial ischemia and reperfusion. To determine
the contribution of reversal of the U1 mechanism to ische-
mia-induced NE release, 1 of the microdialysis probes in the
ischemic myocardium was coperfused with the U1 inhibitor
desipramine (DMI).12,13
We also determined whether sympathetic nerve endings
are functionally impaired during reperfusion after severe
myocardial ischemia, as has been suggested for the isolated
rat hearts.2 For this purpose, local NE response to an
intracoronary infusion of tyramine in the postischemic myo-
cardium was compared with the response observed in the
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nonischemic porcine myocardium of control animals previ-
ously studied under similar experimental conditions.12 Tyra-
mine is taken up via U1 into the sympathetic nerve endings,
where it releases NE. Tyramine thus provides information on




All experiments were performed in accordance with the Guiding
Principles for Research Involving Animals and Human Beings as
approved by the Council of the American Physiological Society and
under the regulations of the Animal Care Committee of Erasmus
University Rotterdam.
Surgical Procedure
After an overnight fast, crossbred Landrace3Yorkshire pigs of either
sex (weight 30 to 35 kg, n59) were sedated with ketamine (20 to 25
mg/kg IM), anesthetized with sodium pentobarbital (20 mg/kg IV),
intubated, and connected to a respirator for intermittent positive
pressure ventilation with a mixture of oxygen and nitrogen. Respi-
ratory rate and tidal volume were set to keep arterial blood gases
within the normal range.12,14
Catheters were positioned in the superior caval vein for the
continuous administration of sodium pentobarbital (10 to 15 mg z
kg21 z h21) and saline to replace blood withdrawn during sampling. In
the descending aorta, a fluid-filled catheter was placed to monitor
aortic blood pressure and blood sampling. Through a carotid artery,
a micromanometer-tipped catheter (B. Braun Medical BV) was
inserted into the left ventricle (LV) for the measurement of LV
pressure and its first derivative, LV dP/dt. After the administration of
pancuronium bromide (4 mg), a midsternal thoracotomy was per-
formed, and the heart was suspended in a pericardial cradle. An
electromagnetic flow probe (Skalar) was then placed around the
ascending aorta for the measurement of cardiac output. After a
Doppler flow probe was placed on a proximal segment of the left
anterior descending coronary artery (LAD), a cannula (outer diam-
eter51.3 mm) was inserted distal to this site into the LAD for the
administration of tyramine.
Microdialysis probes were implanted in the LV myocardium
through the use of a steel guiding needle and split plastic tubing: 1
probe in the region perfused by the left circumflex coronary artery
(LCx) and 2 probes in the area perfused by the LAD. To achieve
local U1 inhibition, 1 of the LAD probes was coperfused with DMI
(100 mmol/L).13 In addition, a microdialysis probe was placed in the
interventricular coronary vein that drains the LAD region.15
Dialysis Methodology
The polycarbonate dialysis membrane of the microdialysis probes
(CMA/20; Carnegie Medicine AB) has a cutoff value of 20 kDa, a
length of 10 mm, and a diameter of 0.5 mm. Probes were perfused
with an isotonic Ringer’s solution at a rate of 2 mL/min with a
CMA/100 microinjection pump. Dialysate volumes of 20 mL (sam-
pling time 10 minutes) were collected in microvials containing 20
mL of a solution of 2% (wt/vol) EDTA and 30 nmol/L l-erythro-a-
methyl-NE (AMN) as internal standard in 0.08 N acetic acid.
Sampling started immediately after insertion of the probes. Plasma
samples were drawn into chilled heparin-containing tubes containing
12 mg glutathione. Microdialysis and plasma samples were stored at
280°C until analysis within the next 5 days.12,16
In vivo probe recovery of NE (5261%) has been determined
through retrodialysis with AMN as a calibrator and direct compari-
son of hemomicrodialysis and plasma samples.12,17 In vivo probe
recovery for E (6863%) was determined through a comparison of E
concentrations in arterial plasma with E concentrations in the
dialysate obtained from the carotid artery probe. The in vivo probe
recovery for DA was not determined directly but was assumed to be
similar to the probe recovery of NE because of the similarities of NE
and DA in size and charge distribution.
Experimental Protocol
After a 120-minute stabilization period,12 baseline measurements
were obtained during a 30-minute period before the LAD was
occluded distal to the first diagonal branch for 60 minutes, with an
atraumatic clip, and then reperfused for 150 minutes. During the final
30 minutes of reperfusion, tyramine (154 nmol z kg21 z min21) was
infused directly into the LAD. At the end of the experiment, the
perfusion area of the LAD was determined with an intra-atrial
infusion of 30 mL of a 5% (wt/wt) solution of fluorescein sodium
during reocclusion of the LAD. During occlusion, ventricular ar-
rhythmias were counted and distinguished as premature ventricular
contractions, ventricular tachycardia, or ventricular fibrillation.18
After the induction of ventricular fibrillation with a 9-V battery, the
heart was excised and infarct size was determined with the use of
para–nitro blue tetrazolium.14
Analytical Procedures
Plasma catecholamines were determined through HPLC with fluoro-
metric detection after liquid-liquid extraction and derivatization with
the fluorogenic agent 1,2-diphenyl-ethylenediamine.19 For microdi-
alysis samples, the catecholamines are not extracted before fluoro-
metric detection with HPLC but instead were directly derivatized
according to the procedure described by Alberts et al.17 This method
suppresses the interference of sulfhydryl compounds on derivatiza-
tion, thus improving sensitivity.
Reagents and Pharmaceuticals
Ketamine and sodium pentobarbital were obtained from Apharmo
BV. Pancuronium bromide was obtained from Organon Teknica BV.
Ringer’s solution was purchased from Baxter. Tyramine was ob-
tained from the Department of Pharmacy, University Hospital
Rotterdam. Fluorescein sodium, para–nitro blue tetrazolium, DMI,
NE, E, DA, and AMN were purchased from Sigma Chemical Co.
EDTA was purchased from Merck. L-Glutathione was obtained from
Fluka. Acetic acid was obtained from Baker. 1,2-Diphenyl-
ethylenediamine was prepared as reported previously.19
Statistical Analysis
Five of the 9 animals experienced ventricular fibrillation during LAD
occlusion (between 10 and 30 minutes of ischemia) but were
successfully defibrillated within 1 minute with the use of 20- to
30-W countershocks and therefore were included in the analysis.
Because there were no differences in the hemodynamic and cate-
cholamine responses between animals that fibrillated and the animals
that maintained sinus rhythm, the data for all 9 animals were pooled.
Catecholamine concentrations obtained with microdialysis were
corrected for probe recovery. Lower limits of detection for catechol-
amines measured with microdialysis and those measured in arterial
plasma were 0.2 and 0.02 nmol/L, respectively. Baseline values were
determined by averaging the 3 measurements during the 30-minute
period before occlusion.12 Results are expressed as mean6SEM. For
statistical analysis, 2-way ANOVA, 1-way ANOVA for repeated
measures with Dunnett’s multiple comparison test as post hoc test,
and Student’s t tests were used as appropriate.
Results
Systemic Hemodynamics During Ischemia
and Reperfusion
Baseline hemodynamic data and the changes produced with
60-minute LAD occlusion and 120 minutes of reperfusion
(Table 1) are in accordance with previously published data
from our laboratory.14
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Infarct Size
The LAD occlusion resulted in an ischemic area (area at risk)
that composed 2962% of the LV mass. Infarct size deter-
mined at the end of reperfusion was 8464% of the area at
risk.
Catecholamine Concentrations During Ischemia
and Reperfusion
At baseline, NE concentrations in MIF (NEMIF) in the LAD
and LCx regions were similar to concentrations in the
coronary vein (NECV) but were 3 times the concentrations in
arterial plasma (NEart) (P,0.05; Table 2). DA concentrations
followed a similar pattern, whereas E was detectable only in
arterial plasma. Under U1 blockade, NEMIF increased 5-fold,
whereas DAMIF did not change and EMIF remained
undetectable.
During the first 10 minutes of ischemia, NEMIF in the
LAD region tripled and continued to rise progressively, so
NEMIF increased 500-fold by the end of ischemia (Table 2,
Figure 1). In the presence of U1 blockade, the rate of rise
of NEMIF was attenuated so that after 20 minutes of
ischemia NEMIF under U1 blockade was similar to, and at
60 minutes was less than half of NEMIF in the absence of U1
blockade. NECV increased progressively to 100-fold its
baseline value. On reperfusion, NEMIF under U1 blockade
and NECV declined rapidly, with the early rate of decline
being most pronounced for NEMIF in the absence of U1
blockade (Figure 1). Within 120 minutes of reperfusion,
catecholamine concentrations in MIF and coronary vein
had returned to baseline values. NEMIF in the LCx perfused
area and NEart remained unchanged during the course of
the experiment.
In the LAD region, EMIF and DAMIF in the absence and
presence of U1 blockade and ECV and DACV followed quali-
tatively similar patterns as NE, but absolute increments
during ischemia were substantially less pronounced (Table 2,
TABLE 1. Cardiac and Systemic Hemodynamics at Baseline, at 60 Min of






Mean arterial pressure, mm Hg 9762 8262* 7965
Cardiac output, L/min 2.460.2 2.160.1 1.860.1*
Heart rate, bpm 11464 11867 137611*
Systemic vascular
resistance, mm Hg z min21 z L21
4264 4164 4365
Stroke volume, mL 2262 1861* 1562*
LV dP/dtmax, mm Hg/s 16806100 14606110 13806150
Left ventricular end-diastolic pressure, mm Hg 6.660.8 9.361.4 10.061.9*
LAD flow, mL/min 3463 0 4668
Values are given as mean6SEM (n59).
*P,0.05 vs baseline.
TABLE 2. Circulatory and Interstitial Catecholamine Concentrations at Baseline, at 60 Min of












Baseline 0.3060.08 0.8660.22† 0.9760.11† 5.7660.77†‡§ 0.9660.13†
Ischemia 0.3260.07 90636*† 5246125*†‡ 198646*†‡§ 0.7960.27†‡§
Reperfusion 0.5460.23 0.6260.30 0.5460.11 1.9960.28*†‡§ 0.6260.16
E
Baseline 0.0460.01 ,0.20 ,0.20 ,0.20 ,0.20
Ischemia 0.0360.01 2.5561.07*† 4.7460.71*† 2.0960.43*†§ ,0.20‡§
Reperfusion 0.0760.02 ,0.20 ,0.20 ,0.20 ,0.20
DA
Baseline 0.0660.01 0.7160.45† 0.4060.12† 0.5760.16† 0.5960.27†
Ischemia 0.0660.01 11.664.3*† 43.969.5*†‡ 16.565.6*†§ 0.4760.04†‡§
Reperfusion 0.1560.07 0.2760.11 0.3060.10† 0.3460.13† 0.2160.03
Values are given as mean6SEM (n59).
*P,0.05 vs baseline.
†P,0.05 vs arterial plasma.
‡P,0.05 vs coronary vein.
§P,0.05 vs MIF LADCA.
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Figure 1). Again, Eart, DAart, and DAMIF in the LCx region did
not change over the course of the experiment, whereas EMIF in
the LCx region remained undetectable.
Ventricular Arrhythmias During Ischemia
Most of the ventricular arrhythmias occurred within the first
30 minutes of ischemia. The incidence of premature ventric-
ular contractions was particularly high between 20 to 30
minutes of ischemia (a total of 661 and a mean of 73619 per
animal). Five animals experienced ventricular fibrillation but
were defibrillated successfully within 1 minute. There was no
correlation between NEMIF concentrations and the occurrence




Figure 2 shows that the infusion of tyramine directly into the
LAD after 120 minutes of reperfusion caused an increase in
NEMIF in the postischemic myocardium from 0.660.1 to
11.561.9 nmol/L (P,0.05). This increment was not different
from the increase of from 0.960.2 to 13.463.2 nmol/L in the
LAD region of the normal (nonischemic) swine heart.12
Furthermore, compared with the increment seen in the ab-
sence of U1 blockade, the increase in the presence of U1
blockade was minimal.
Discussion
The results of the present study demonstrate that myocardial
ischemia is associated with a rapid and massive increase in
the concentration of all 3 endogenous catecholamines (NE, E,
and DA) in the myocardial interstitial fluid as measured with
the microdialysis technique in vivo. As suggested for NE in in
vitro studies,5,6 the reversed U1 mechanism plays an impor-
tant role in the release of all 3 catecholamines during
ischemia in vivo. Furthermore, our study shows that after 60
minutes of ischemia, which results in massive infarction of
the jeopardized myocardium, the functional integrity of
sympathetic nerve terminals remains intact. Finally, our
results suggest that cardiac interstitial E has a neuronal origin.
Interstitial Catecholamine Concentrations During
Basal Conditions
The present study confirms that at baseline, NEMIF is ’3
times the NEart and increases ’6-fold in response to U1
blockade,1,12,20 whereas EMIF was below the detection limit
regardless of the presence of U1 inhibition. DAMIF did not rise
under U1 blockade, suggesting that U1 does not play a
predominant role in the clearance of DA from the interstitial
compartment under baseline conditions in the heart. Little is
known about the affinity of DA for U1 and the relevance of
U1 to DA clearance in the heart. Because the main purpose of
the U1 mechanism is to modulate synaptic transmission, it is
hard to envisage a substantial role for U1 in the clearance of
DA in the absence of any cardiac dopaminergic synaptic
transmission. Furthermore, in tissues with known dopaminer-
gic transmission, like brain and kidney, DA is taken up by a
specific DA neuronal uptake mechanism that does not take up
NE and is poorly inhibited by DMI.21,22
Interstitial Catecholamine Concentrations During
Ischemia and Reperfusion
In in vitro experiments in isolated rat hearts, 3 phases of
ischemia-induced release of NE, each with a different mech-
anism, have been recognized.2,5,6,23 During the early phase of
ischemia (0 to 10 minutes), the release of NE, if present, is
Figure 1. Time course of changes in catecholamine concentrations during ischemia and reperfusion. Data are shown for MIF in LAD
region in absence (F) and presence (E) of U1 blockade, MIF in LCx region in absence of U1 blockade (3), and concentrations in arteri-
al plasma (hatched bars) and in coronary vein (). Data are given as mean6SEM (n59).
Figure 2. Tyramine-induced NE release in perfusion area of
LAD with and without U1 inhibition. Data are shown for postis-
chemic myocardium (n54, hatched bars) and for historic nonis-
chemic control animals (n54, solid bars).12 Data are given as
mean6SEM (n54). *P,0.05.
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exocytotic and depends on the activation of efferent sympa-
thetic neurons. Accumulation of catecholamines in the extra-
cellular space during this early phase is prevented by the
highly efficient U1 mechanism and by presynaptic inhibition
by adenosine, which accumulates in cardiac tissue during this
phase of ischemia. The latter has been shown to be of
particular importance in the rat, because adenosine concen-
trations are considerably higher than those in other species.24
During the second phase of ischemia (10 to 40 minutes), the
release of NE becomes nonexocytotic and is thought to
involve the U1 mechanism in the carrier-mediated efflux of
NE in reverse of its normal transport direction.5,6 During the
third phase (.40 minutes ischemia), the release of NE is no
longer attenuated by U1 inhibitors, which is explained by the
occurrence of structural changes in the neuronal membrane of
the myocardial neurons.2
In the present study, a rapid and pronounced increase in
MIF concentrations of all 3 catecholamines was observed
shortly after occlusion of the LAD. Because released NE is
avidly taken up by the cardiac U1 mechanism, we expected a
larger rise in NEMIF in the presence of the U1 inhibitor DMI
than without U1 inhibition. However, during this first 10
minutes of ischemia, the increment of NEMIF with U1 block-
ade (5.8 to 8.5 nmol/L) was similar to the increment without
U1 blockade (0.9 to 2.7 nmol/L). Possibly, in the parasym-
pathetically dominant porcine heart, U1 carrier–mediated
nonexocytotic NE efflux already occurred within the initial
10 minutes of ischemia, so in the presence of DMI, any
decrease in U1-mediated clearance was compensated for by a
decrease in the ischemia-induced U1 carrier–mediated NE
efflux. As mentioned, myocardial release of NE in first 10
minutes of ischemia is not an invariable finding. For example,
stimulation-evoked NE release has shown to be suppressed in
rat hearts and human atrial tissue but to be facilitated in
guinea pig hearts.25
Throughout the ischemic period, MIF catecholamine con-
centrations rose progressively in the ischemic area. Concen-
trations of catecholamines did not change in either the
nonischemic LCx area or the systemic circulation. The
reversal of the U1 mechanism continued to contribute to the
catecholamine release during the entire period of ischemia.
Thus, U1 blockade attenuated the release of all catechol-
amines by .50%, indicating that despite infarction of 83% of
the area at risk, U1 was operative after 60 minutes of
ischemia. Our findings vary from those obtained in the
ischemic myocardium of the isolated rat heart, where the
reversed U1 mechanism no longer contributes to the release
of catecholamines 40 minutes after the induction of ischemia.
This difference may be explained by the differences in
experimental conditions (eg, in vivo versus in vitro studies)
and the species investigated.2
On reperfusion, MIF catecholamine concentrations rapidly
declined in the postischemic myocardium. Washout probably
was the predominant factor in the clearance of catechol-
amines in this early phase of reperfusion. However, the
decline in the first 10 minutes of reperfusion was substan-
tially greater without inhibition of the U1 mechanism, indi-
cating that the U1 mechanism also contributed significantly
to the clearance of NE during early reperfusion. Although it
should be noted that in contrast to techniques used in in vitro
studies,2,25 the time resolution of the MD technique as
presently used does not allow conclusions to be made
regarding minute-to-minute changes in catecholamine con-
centrations. Compatible with previous findings that E and DA
are less avidly taken up by U1 than NE,26 the decline in EMIF
and DAMIF during reperfusion was not affected by U1
blockade.
Origin of Myocardial Interstitial E
An interesting finding was the ischemia-induced increase in
EMIF, albeit small compared with the increase in NEMIF. Because
the concentrations of Eart and EMIF in the nonischemic LCx region
did not change during ischemia, this increase must have origi-
nated from the heart. It is currently unclear whether this source
is neuronal or extraneuronal. Evidence favoring extraneuronal
synthesis and release of E is the presence of the enzyme
phenylethanolamine N-methyltransferase in extraneuronal myo-
cardial tissue.10,27 Furthermore, an intrinsic cardiac adrenergic
cell type outside the sympathetic nervous system, capable of
releasing E and NE, has been identified in the human heart.10
Finally, enhanced cardiac E spillover into the coronary circula-
tion of patients with heart failure during sympathetic stimulation
was disproportionate to the spillover of NE, suggesting that E
may in part be derived from sources other than chromaffin cells
or sympathetic nerves.9,11 On the other hand, it is known that
sympathetic neurons can take up E from the circulation and
release it upon stimulation.28 In the present study, the pattern of
release and clearance of E during ischemia and reperfusion was
similar to that of NE and DA. Furthermore, inhibition of the
neuronal U1 mechanism attenuated the ischemia-induced release
of all catecholamines to a similar degree, suggesting a common
source, thus favoring a neuronal origin.
Functional Integrity of Sympathetic Nerve Endings
The effects of U1 blockade on the NEMIF responses to
ischemia and reperfusion suggested that U1 mechanism of
the sympathetic nerves was still functioning during and
after the 60-minute LAD occlusion. This is further sub-
stantiated by the NEMIF response to tyramine at the end of
reperfusion. Similar to NE, tyramine is taken up by
neurons through U1, where it displaces NE from the nerve
terminals because of its higher affinity for the neuronal
storage proteins. Consequently, the tyramine-induced NE
release reflects both neuronal NE content and the efficacy
of U1.12,29 The increase in NEMIF in the postischemic LAD
region was very similar to that in the nonischemic control
hearts (Figure 2).12 These findings are in line with those
reported by Shindo et al,4 who studied the tyramine-
induced NE release in nonischemic and postischemic areas
in feline hearts after 40 minutes of reperfusion after 40
minutes of ischemia. In addition, in the present study, the
attenuation of the tyramine-induced NE release by U1
inhibition in both postischemic and nonischemic groups
also was similar (Figure 2). Although the present experi-
mental setup does not allow for any predictions concerning
the long-term survival of sympathetic nerves, the present
findings indicate that sympathetic nerve terminals re-
mained functionally intact at least during the first few
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hours after reperfusion. However, functional alterations of
the somata of the sympathetic nerves cannot be entirely
excluded. Thus, in a canine model of tachycardia-induced
heart failure, impairment of the myocardial contractile
response to electrical or chemical stimulation of sympa-
thetic somata was observed at a time when the contractile
response to tyramine was completely preserved.30
Implications
Although the pathophysiological significance of the massive
accumulation of catecholamines in the ischemic myocardial
tissue was not investigated in the present study, there is
evidence from experimental as well as clinical studies that
high catecholamine concentrations are deleterious to the
heart.31–34 Several studies have demonstrated NE-dependent
antiarrhythmic effects of U1 inhibition during ischemia with
either tricyclic antidepressant agents like desipramine and
imipramine or structurally unrelated U1 inhibitors like co-
caine and nisoxetine.7,35 This study provides a possible
explanation for this beneficial effect by demonstrating that
the reversed U1 mechanism contributes substantially to the
release of catecholamines during ischemia.
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